Mauro Maccarrone

Prof. Dr. Mauro Maccarrone

1. Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
Mauro MaccarroneMauro Maccarrone
Mauro Maccarrone
IBItai Bab
Itai Bab
TBTamás Bíró
Tamás Bíró
GCGuy A. Cabral
Guy A. Cabral
SDSudhansu K. Dey
Sudhansu K. Dey
AZAndreas Zimmer
Andreas Zimmer

29 January 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Valerio ChiurchiùValerio Chiurchiù
Valerio Chiurchiù
Alessandro LeutiAlessandro Leuti
Alessandro Leuti
Mauro MaccarroneMauro Maccarrone
Mauro Maccarrone
Inflammation is an immune response that works as a contained fire that is pre-emptively sparked as a defensive process during infections or upon any kind of tissue insult, and that is spontaneously extinguished after elimination or termination of the damage. However, persistent and uncontrolled immune reactions act as a wildfire that promote chronic inflammation, unresolved tissue damage and, eventually, chronic diseases. A wide network of soluble mediators, among which endogenous bioactive lipids, governs all immune processes. They are secreted by basically all cells involved in inflammatory processes and constitute the crucial infrastructure that triggers, coordinates and confines inflammatory mechanisms. However, these molecules are also deeply involved in the detrimental transition from acute to chronic inflammation, be it for persistent or excessive action of pro-inflammatory lipids or for the impairment of the functions carried out by resolving ones. As a matter of fact, bioactive lipids have been linked, to date, to several chronic diseases, including rheumatoid arthritis, atherosclerosis, diabetes, cancer, inflammatory bowel disease, systemic lupus erythematosus, and multiple sclerosis. This review summarizes current knowledge on the involvement of the main classes of endogenous bioactive lipids—namely classical eicosanoids, pro-resolving lipid mediators, lysoglycerophospholipids/sphingolipids, and endocannabinoids—in the cellular and molecular mechanisms that lead to the pathogenesis of chronic disorders.

1 January 2020 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
ALAlessandro Leuti
Alessandro Leuti
DFDomenico Fazio
Domenico Fazio
MFMarina Fava
Marina Fava
APAlessandra Piccoli
Alessandra Piccoli
SOSergio Oddi
Sergio Oddi
Mauro MaccarroneMauro Maccarrone
Mauro Maccarrone

3 January 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMarjolein Soethoudt
Marjolein Soethoudt
UGUwe Grether
Uwe Grether
JFJürgen Fingerle
Jürgen Fingerle
TGTravis W. Grim
Travis W. Grim
FFFilomena Fezza
Filomena Fezza
MSMario van der Stelt
Mario van der Stelt
The cannabinoid CB2receptor (CB2R) represents a promising therapeutic target for various forms of tissue injury and inflammatory diseases. Although numerous compounds have been developed and widely used to target CB2R, their selectivity, molecular mode of action and pharmacokinetic properties have been poorly characterized. Here we report the most extensive characterization of the molecular pharmacology of the most widely used CB2R ligands to date. In a collaborative effort between multiple academic and industry laboratories, we identify marked differences in the ability of certain agonists to activate distinct signalling pathways and to cause off-target effects. We reach a consensus that HU910, HU308 and JWH133 are the recommended selective CB2R agonists to study the role of CB2R in biological and disease processes. We believe that our unique approach would be highly suitable for the characterization of other therapeutic targets in drug discovery research.

9 June 2017 in Science
Verified
Journal Article
Closed access
PDF file
AEAnnelot C. M. van Esbroeck
Annelot C. M. van Esbroeck
AJAntonius P. A. Janssen
Antonius P. A. Janssen
ACArmand B. Cognetta
Armand B. Cognetta
DODaisuke Ogasawara
Daisuke Ogasawara
GSGuy Shpak
Guy Shpak
MSMario van der Stelt
Mario van der Stelt
A clue to a drug's neurotoxicity?: The drug BIA 10-2474 inhibits fatty acid amide hydrolase (FAAH), a lipase that degrades a specific endocannabinoid. On the basis of this activity, BIA 10-2474 was being developed as a potential treatment for anxiety and pain. In a phase 1 trial of the drug, one subject died, and four others suffered brain damage. As an initial step in investigating whether inhibition of off-target proteins by BIA 10-2474 might contribute to its clinical neurotoxicity, van Esbroeck et al. used activity-based proteomic assays to identify proteins targeted by the drug. Studying human cells and brain samples from subjects not associated with the trial, they found that BIA 10-2474 targeted several different lipases in addition to FAAH. It also substantially altered lipid metabolism in cultured neurons. Science , this issue p. 1084

20 November 2014 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PDF file
Mauro MaccarroneMauro Maccarrone
Mauro Maccarrone
MGManuel Guzmán
Manuel Guzmán
KMKen Mackie
Ken Mackie
PDPatrick Doherty
Patrick Doherty
THTibor Harkany
Tibor Harkany